{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:28:45Z","timestamp":1793842125136,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Benign prostatic hyperplasia (BPH) is a common age-associated disease whose prevalence rises sharply with advancing age. Therapeutic responses to 5\u03b1-reductase inhibitors (5-ARIs) in BPH are heterogeneous and may ultimately culminate in the need for surgery; however, the mechanisms that permit disease progression during treatment remain unclear. Here we integrate spatial and single-cell transcriptomics with functional perturbations and mouse genetics to delineate a macrophage-orchestrated pyroptosis\u2013senescence\u2013club axis in the human prostate. In 5-ARI-exposed tissue, we observe enrichment of cleaved-GSDMD\u207a macrophages, elevated epithelial p16\n                    <jats:sup>INK4A<\/jats:sup>\n                    expression and expansion of SCGB1A1\u207a club cells. Spatial mapping pinpoints macrophage\u2013epithelium hotspots with prominent MIF\u2013CD74 and HMGB1\u2013AGER signaling. Under 5-ARI pressure, luminal-cell secretomes recruit macrophages via MIF\u2013CD74, and pyroptotic macrophages release HMGB1 that activates epithelial AGER to trigger luminal G1 arrest and senescence, which in turn promotes luminal-to-club reprogramming through a partially Notch-associated program. Blockade of MIF\u2013CD74 or HMGB1\u2013AGER attenuates macrophage pyroptosis and luminal senescence, whereas Notch inhibition partially reverses epithelial remodeling. A 13-gene pyroptosis\u2013macrophage signature (PM-13) stratifies patient responsiveness to 5-ARIs. In a castration\/testosterone-induced mouse BPH model, 5-ARI treatment amplifies pyroptotic macrophages and club programs, whereas Gsdmd deletion blunts pyroptosis and dampens senescence\/club transcriptional states. These findings nominate druggable nodes\u2014MIF\u2013CD74, HMGB1\u2013AGER, Notch and GSDMD\u2014as candidate targets for therapeutic intervention and patient stratification in BPH under 5-ARI therapy.\n                  <\/jats:p>\n                  <jats:p>Keywords: spatial and single-cell transcriptomics; benign prostatic hyperplasia; 5-alpha-reductase inhibitors; cellular senescence; macrophage pyroptosis; luminal-to-club conversion; MIF\u2013CD74\/HMGB1\u2013AGER signaling; GSDMD.<\/jats:p>","DOI":"10.1038\/s12276-026-01864-3","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:26:27Z","timestamp":1791357987000},"page":"3514-3533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Macrophage pyroptosis drives luminal senescence and club-cell reprogramming in 5\u03b1-reductase inhibitor-treated prostatic hyperplasia"],"prefix":"10.1038","volume":"58","author":[{"given":"Zheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiancheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0938-0308","authenticated-orcid":false,"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1864_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/jama.2025.7045","volume":"334","author":"JT Wei","year":"2025","unstructured":"Wei, J. T., Dauw, C. A. & Brodsky, C. N. Lower urinary tract symptoms in men: a review. J. Am. Med. Assoc. 334, 809\u2013821 https:\/\/doi.org\/10.1001\/jama.2025.7045 (2025).","journal-title":"J. Am. Med. Assoc."},{"key":"1864_CR2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry, S. J., Coffey, D. S., Walsh, P. C. & Ewing, L. L. The development of human benign prostatic hyperplasia with age. J. Urol. 132, 474\u2013479 https:\/\/doi.org\/10.1016\/S0022-5347(17)49698-4 (1984).","journal-title":"J. Urol."},{"key":"1864_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","volume":"84","author":"S Gravas","year":"2023","unstructured":"Gravas, S. et al. Summary paper on the 2023 European association of urology guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur. Urol. 84, 207\u2013222 https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008 (2023).","journal-title":"Eur. Urol."},{"key":"1864_CR4","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1038\/ijir.2008.55","volume":"20","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn, C. G. Pathology of benign prostatic hyperplasia. Int. J. Impot. Res. 20, S11\u2013S18 https:\/\/doi.org\/10.1038\/ijir.2008.55 (2008).","journal-title":"Int. J. Impot. Res."},{"key":"1864_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40779-024-00569-w","volume":"11","author":"H Zi","year":"2024","unstructured":"Zi, H. et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil. Med. Res. 11, 64 https:\/\/doi.org\/10.1186\/s40779-024-00569-w (2024).","journal-title":"Mil. Med. Res."},{"key":"1864_CR6","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","volume":"3","author":"AF Awedew","year":"2022","unstructured":"Awedew, A. F. et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 3, e754\u2013e776 https:\/\/doi.org\/10.1016\/S2666-7568(22)00213-6 (2022).","journal-title":"Lancet Healthy Longev."},{"key":"1864_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06628-8","volume":"7","author":"SWH Lee","year":"2017","unstructured":"Lee, S. W. H., Chan, E. M. C. & Lai, Y. K. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci. Rep. 7, 7984 https:\/\/doi.org\/10.1038\/s41598-017-06628-8 (2017).","journal-title":"Sci. Rep."},{"key":"1864_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJM199802263380901","volume":"338","author":"JD McConnell","year":"1998","unstructured":"McConnell, J. D. et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N. Engl. J. Med. 338, 557\u2013563 https:\/\/doi.org\/10.1056\/NEJM199802263380901 (1998).","journal-title":"N. Engl. J. Med."},{"key":"1864_CR9","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell, J. D. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349, 2387\u20132398 https:\/\/doi.org\/10.1056\/NEJMoa030656 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1864_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","volume":"5","author":"EH Kim","year":"2018","unstructured":"Kim, E. H., Brockman, J. A. & Andriole, G. L. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J. Urol. 5, 28\u201332 https:\/\/doi.org\/10.1016\/j.ajur.2017.11.005 (2018).","journal-title":"Asian J. Urol."},{"key":"1864_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7326\/M23-0113","volume":"176","author":"GW Smetana","year":"2023","unstructured":"Smetana, G. W., Smith, C. C., Singla, A. & Libman, H. How would you manage this patient with benign prostatic hyperplasia? Grand rounds discussion from Beth Israel Deaconess Medical Center. Ann. Intern. Med. 176, 545\u2013555 https:\/\/doi.org\/10.7326\/M23-0113 (2023).","journal-title":"Ann. Intern. Med."},{"key":"1864_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/bju.12802","volume":"115","author":"MA Kozminski","year":"2015","unstructured":"Kozminski, M. A., Wei, J. T., Nelson, J. & Kent, D. M. Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia. BJU Int. 115, 308\u2013316 https:\/\/doi.org\/10.1111\/bju.12802 (2015).","journal-title":"BJU Int."},{"key":"1864_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202401906","volume":"9","author":"X Xu","year":"2025","unstructured":"Xu, X. et al. Decoding benign prostatic hyperplasia: Insights from multi-fluid metabolomic analysis. Small Methods 9, e2401906 https:\/\/doi.org\/10.1002\/smtd.202401906 (2025).","journal-title":"Small Methods"},{"key":"1864_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157237","volume":"147","author":"L Chen","year":"2025","unstructured":"Chen, L. et al. Typhae Pollen active subfraction exerts antiangiogenic effect in benign prostatic hyperplasia via regulating the VEGF signaling pathway and arachidonic acid metabolism. Phytomedicine 147, 157237 https:\/\/doi.org\/10.1016\/j.phymed.2025.157237 (2025).","journal-title":"Phytomedicine"},{"key":"1864_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07783-x","volume":"16","author":"J Li","year":"2025","unstructured":"Li, J. et al. TNF-alpha modulates cell proliferation via SOX4\/TGF-beta\/Smad signaling in benign prostatic hyperplasia. Cell Death Dis. 16, 472 https:\/\/doi.org\/10.1038\/s41419-025-07783-x (2025).","journal-title":"Cell Death Dis."},{"key":"1864_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/acel.70180","volume":"24","author":"Z Li","year":"2025","unstructured":"Li, Z. et al. Single-cell sequencing reveals that CD4+ T cells eliminate senescent prostate epithelium to delay progression of benign prostatic hyperplasia. Aging Cell 24, e70180 https:\/\/doi.org\/10.1111\/acel.70180 (2025).","journal-title":"Aging Cell"},{"key":"1864_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-021-00496-8","volume":"18","author":"G Fiard","year":"2021","unstructured":"Fiard, G. et al. Cellular senescence as a possible link between prostate diseases of the ageing male. Nat. Rev. Urol. 18, 597\u2013610 https:\/\/doi.org\/10.1038\/s41585-021-00496-8 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"1864_CR18","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. Elucidating cellular senescence-related genes in benign prostatic hyperplasia through mendelian randomization and single-cell RNA sequencing. J. Gerontol. A 80, glaf073 https:\/\/doi.org\/10.1093\/gerona\/glaf073 (2025).","DOI":"10.1093\/gerona\/glaf073"},{"key":"1864_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41573-024-01074-4","volume":"24","author":"D McHugh","year":"2025","unstructured":"McHugh, D., Duran, I. & Gil, J. Senescence as a therapeutic target in cancer and age-related diseases. Nat. Rev. Drug Discov. 24, 57\u201371 https:\/\/doi.org\/10.1038\/s41573-024-01074-4 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1864_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang, B., Han, J., Elisseeff, J. H. & Demaria, M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell Biol. 25, 958\u2013978 https:\/\/doi.org\/10.1038\/s41580-024-00727-x (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1864_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108906","volume":"274","author":"SL Jiang","year":"2025","unstructured":"Jiang, S. L. et al. Macrophages at the crossroads of cellular senescence and cancer development and progression: therapeutic opportunities and challenges. Pharmacol. Ther. 274, 108906 https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108906 (2025).","journal-title":"Pharmacol. Ther."},{"key":"1864_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29719-1","volume":"13","author":"RE Vickman","year":"2022","unstructured":"Vickman, R. E. et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nat. Commun. 13, 2133 https:\/\/doi.org\/10.1038\/s41467-022-29719-1 (2022).","journal-title":"Nat. Commun."},{"key":"1864_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0744-1","volume":"9","author":"J Sheng","year":"2018","unstructured":"Sheng, J. et al. M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. Cell Death Dis. 9, 755 https:\/\/doi.org\/10.1038\/s41419-018-0744-1 (2018).","journal-title":"Cell Death Dis."},{"key":"1864_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","volume":"23","author":"L Vande Walle","year":"2024","unstructured":"Vande Walle, L. & Lamkanfi, M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat. Rev. Drug Discov. 23, 43\u201366 https:\/\/doi.org\/10.1038\/s41573-023-00822-2 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1864_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-025-00837-0","volume":"26","author":"Y Bai","year":"2025","unstructured":"Bai, Y., Pan, Y. & Liu, X. Mechanistic insights into gasdermin-mediated pyroptosis. Nat. Rev. Mol. Cell Biol. 26, 501\u2013521 https:\/\/doi.org\/10.1038\/s41580-025-00837-0 (2025).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1864_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-024-01958-2","volume":"9","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Pyroptosis in health and disease: mechanisms, regulation and clinical perspective. Signal Transduct. Target. Ther. 9, 245 https:\/\/doi.org\/10.1038\/s41392-024-01958-2 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1864_CR27","doi-asserted-by":"publisher","first-page":"e0191469","DOI":"10.1371\/journal.pone.0191469","volume":"13","author":"J Li","year":"2018","unstructured":"Li, J. et al. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PLoS ONE 13, e0191469 https:\/\/doi.org\/10.1371\/journal.pone.0191469 (2018).","journal-title":"PLoS ONE"},{"key":"1864_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3892\/etm.2014.1680","volume":"8","author":"BC Yang","year":"2014","unstructured":"Yang, B. C., Jin, L. L., Yang, Y. F., Li, K. & Peng, D. M. Inhibitory effect of rape pollen supercritical CO2 fluid extract against testosterone-induced benign prostatic hyperplasia in rats. Exp. Ther. Med. 8, 31\u201337 https:\/\/doi.org\/10.3892\/etm.2014.1680 (2014).","journal-title":"Exp. Ther. Med."},{"key":"1864_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/pros.2990090308","volume":"9","author":"SJ Berry","year":"1986","unstructured":"Berry, S. J., Coffey, D. S., Strandberg, J. D. & Ewing, L. L. Effect of age, castration, and testosterone replacement on the development and restoration of canine benign prostatic hyperplasia. Prostate 9, 295\u2013302 https:\/\/doi.org\/10.1002\/pros.2990090308 (1986).","journal-title":"Prostate"},{"key":"1864_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41391-020-00277-1","volume":"24","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 24, 49\u201357 https:\/\/doi.org\/10.1038\/s41391-020-00277-1 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1864_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-017-0172-3","volume":"15","author":"P Ortiz-Montero","year":"2017","unstructured":"Ortiz-Montero, P., Londono-Vallejo, A. & Vernot, J. P. Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence\/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Commun. Signal. 15, 17 https:\/\/doi.org\/10.1186\/s12964-017-0172-3 (2017).","journal-title":"Cell Commun. Signal."},{"key":"1864_CR32","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"JP Coppe","year":"2008","unstructured":"Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853\u20132868 https:\/\/doi.org\/10.1371\/journal.pbio.0060301 (2008).","journal-title":"PLoS Biol."},{"key":"1864_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207383","volume":"10","author":"J Li","year":"2023","unstructured":"Li, J. et al. NLRP3-dependent crosstalk between pyroptotic macrophage and senescent cell orchestrates trauma-induced heterotopic ossification during aberrant wound healing. Adv. Sci. 10, e2207383 https:\/\/doi.org\/10.1002\/advs.202207383 (2023).","journal-title":"Adv. Sci."},{"key":"1864_CR34","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/jcpe.13517","volume":"48","author":"P Zhao","year":"2021","unstructured":"Zhao, P. et al. Hyperglycaemia-associated macrophage pyroptosis accelerates periodontal inflamm-aging. J. Clin. Periodontol. 48, 1379\u20131392 https:\/\/doi.org\/10.1111\/jcpe.13517 (2021).","journal-title":"J. Clin. Periodontol."},{"key":"1864_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.eururo.2006.12.011","volume":"51","author":"G Kramer","year":"2007","unstructured":"Kramer, G., Mitteregger, D. & Marberger, M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol. 51, 1202\u20131216 https:\/\/doi.org\/10.1016\/j.eururo.2006.12.011 (2007).","journal-title":"Eur. Urol."},{"key":"1864_CR36","doi-asserted-by":"publisher","first-page":"18376","DOI":"10.1074\/jbc.M112.355164","volume":"287","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation. J. Biol. Chem. 287, 18376\u201318385 https:\/\/doi.org\/10.1074\/jbc.M112.355164 (2012).","journal-title":"J. Biol. Chem."},{"key":"1864_CR37","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.7150\/ijbs.85089","volume":"19","author":"T Cao","year":"2023","unstructured":"Cao, T. et al. Rapamycin and low-dose IL-2 mediate an immunosuppressive microenvironment to inhibit benign prostatic hyperplasia. Int. J. Biol. Sci. 19, 3441\u20133455 https:\/\/doi.org\/10.7150\/ijbs.85089 (2023).","journal-title":"Int. J. Biol. Sci."},{"key":"1864_CR38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2505797122","volume":"122","author":"WF Wu","year":"2025","unstructured":"Wu, W. F. et al. The role of estrogen receptor beta in maintaining basal cells and modulating the immune environment in the prostate. Proc. Natl Acad. Sci. USA 122, e2505797122 https:\/\/doi.org\/10.1073\/pnas.2505797122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1864_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103866","volume":"86","author":"J Camarano","year":"2025","unstructured":"Camarano, J. et al. Hydrogen sulfide inhibits recruitment of monocyte-derived tumor associated macrophages in glioblastoma by downregulating CXCL12. Redox Biol. 86, 103866 https:\/\/doi.org\/10.1016\/j.redox.2025.103866 (2025).","journal-title":"Redox Biol."},{"key":"1864_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500225","volume":"12","author":"Q Cao","year":"2025","unstructured":"Cao, Q. et al. Nanoparticle-mediated CXCL12-CXCR4 inhibition reprograms macrophages and suppresses gastric carcinoma. Adv. Sci. 12, e00225 https:\/\/doi.org\/10.1002\/advs.202500225 (2025).","journal-title":"Adv. Sci."},{"key":"1864_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jconrel.2025.01.066","volume":"379","author":"SL Cheng","year":"2025","unstructured":"Cheng, S. L. et al. CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma. J. Control. Release 379, 967\u2013981 https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.066 (2025).","journal-title":"J. Control. Release"},{"key":"1864_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.550824","volume":"11","author":"G D\u2019Agostino","year":"2020","unstructured":"D\u2019Agostino, G. et al. Beta-arrestin1 and beta-arrestin2 are required to support the activity of the CXCL12\/HMGB1 heterocomplex on CXCR4. Front. Immunol. 11, 550824 https:\/\/doi.org\/10.3389\/fimmu.2020.550824 (2020).","journal-title":"Front. Immunol."},{"key":"1864_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13046-024-03024-9","volume":"43","author":"L Liu","year":"2024","unstructured":"Liu, L. et al. Blocking the MIF-CD74 axis augments radiotherapy efficacy for brain metastasis in NSCLC via synergistically promoting microglia M1 polarization. J. Exp. Clin. Cancer Res. 43, 128 https:\/\/doi.org\/10.1186\/s13046-024-03024-9 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1864_CR44","doi-asserted-by":"publisher","first-page":"7338","DOI":"10.4049\/jimmunol.180.11.7338","volume":"180","author":"M Krockenberger","year":"2008","unstructured":"Krockenberger, M. et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J. Immunol. 180, 7338\u20137348 https:\/\/doi.org\/10.4049\/jimmunol.180.11.7338 (2008).","journal-title":"J. Immunol."},{"key":"1864_CR45","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3389\/fimmu.2018.01132","volume":"9","author":"CR Figueiredo","year":"2018","unstructured":"Figueiredo, C. R. et al. Blockade of MIF-CD74 signalling on macrophages and dendritic cells restores the antitumour immune response against metastatic melanoma. Front. Immunol. 9, 1132 https:\/\/doi.org\/10.3389\/fimmu.2018.01132 (2018).","journal-title":"Front. Immunol."},{"key":"1864_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02387-9","volume":"21","author":"W Lai","year":"2021","unstructured":"Lai, W. et al. Extracellular HMGB1 interacts with RAGE and promotes chemoresistance in acute leukemia cells. Cancer Cell Int. 21, 700 https:\/\/doi.org\/10.1186\/s12935-021-02387-9 (2021).","journal-title":"Cancer Cell Int."},{"key":"1864_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00201-8","volume":"8","author":"S Jin","year":"2020","unstructured":"Jin, S. et al. Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment. Biomark. Res. 8, 21 https:\/\/doi.org\/10.1186\/s40364-020-00201-8 (2020).","journal-title":"Biomark. Res."},{"key":"1864_CR48","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1242\/dev.034884","volume":"136","author":"PN Tsao","year":"2009","unstructured":"Tsao, P. N. et al. Notch signaling controls the balance of ciliated and secretory cell fates in developing airways. Development 136, 2297\u20132307 https:\/\/doi.org\/10.1242\/dev.034884 (2009).","journal-title":"Development"},{"key":"1864_CR49","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1172\/JCI25167","volume":"116","author":"JW Tyner","year":"2006","unstructured":"Tyner, J. W. et al. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J. Clin. Invest. 116, 309\u2013321 https:\/\/doi.org\/10.1172\/JCI25167 (2006).","journal-title":"J. Clin. Invest."},{"key":"1864_CR50","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891\u2013906 https:\/\/doi.org\/10.1016\/j.cell.2009.10.027 (2009).","journal-title":"Cell"},{"key":"1864_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347\u2013358 https:\/\/doi.org\/10.1038\/nprot.2016.006 (2016).","journal-title":"Nat. Protoc."},{"key":"1864_CR52","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1016\/j.celrep.2018.11.086","volume":"25","author":"GH Henry","year":"2018","unstructured":"Henry, G. H. et al. A cellular anatomy of the normal adult human prostate and prostatic urethra. Cell Rep. 25, 3530\u20133542 https:\/\/doi.org\/10.1016\/j.celrep.2018.11.086 (2018).","journal-title":"Cell Rep."},{"key":"1864_CR53","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/pros.24020","volume":"80","author":"DB Joseph","year":"2020","unstructured":"Joseph, D. B. et al. Urethral luminal epithelia are castration-insensitive cells of the proximal prostate. Prostate 80, 872\u2013884 https:\/\/doi.org\/10.1002\/pros.24020 (2020).","journal-title":"Prostate"},{"key":"1864_CR54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/path.5857","volume":"256","author":"DB Joseph","year":"2022","unstructured":"Joseph, D. B. et al. 5-alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. J. Pathol. 256, 427\u2013441 https:\/\/doi.org\/10.1002\/path.5857 (2022).","journal-title":"J. Pathol."},{"key":"1864_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.6149","volume":"261","author":"FW Huang","year":"2023","unstructured":"Huang, F. W. et al. Club-like cells in proliferative inflammatory atrophy of the prostate. J. Pathol. 261, 85\u201395 https:\/\/doi.org\/10.1002\/path.6149 (2023).","journal-title":"J. Pathol."},{"key":"1864_CR56","doi-asserted-by":"publisher","first-page":"685.e11\u2013","DOI":"10.1016\/j.urolonc.2020.03.025","volume":"38","author":"N Benlier","year":"2020","unstructured":"Benlier, N. et al. A novel diagnostic tool for the detection of bladder cancer: measurement of urinary high mobility group box-1. Urol. Oncol. 38, 685.e11\u2013685.e16 https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.025 (2020).","journal-title":"Urol. Oncol."},{"key":"1864_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/diagnostics5020219","volume":"5","author":"C Pilzweger","year":"2015","unstructured":"Pilzweger, C. & Holdenrieder, S. Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases. Diagnostics 5, 219\u2013253 https:\/\/doi.org\/10.3390\/diagnostics5020219 (2015).","journal-title":"Diagnostics"},{"key":"1864_CR58","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith, I. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 21, 1443\u20131454 https:\/\/doi.org\/10.1016\/S1470-2045(20)30458-7 (2020).","journal-title":"Lancet Oncol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01864-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:03:49Z","timestamp":1793840629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01864-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1864"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01864-3","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}